Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569805 | 0.83 | AKR1B1 (0.38) | AKR1B1ALDH1A1MAPT | |
| Ammonia Solution, Strong SCHEMBL7590346 | 0.79 | MTNR1A (0.44) | MTNR1AMTNR1BNR1H2RIPK1RIPK3 | |
| SCHEMBL9548959 | 0.78 | AKR1B1 (0.51) | AKR1B1ALDH1A1GAAMAPT | |
| SCHEMBL25569811 | 0.77 | AKR1B1 (0.36) | AKR1B1ALDH1A1MAPT | |
| SCHEMBL20424903 | 0.75 | MTNR1A (0.41) | MTNR1AMTNR1BNR1H2RIPK1RIPK3 | |
| SCHEMBL25569856 | 0.75 | HDAC4 (0.37) | AKR1B1ALDH1A1MAPT | |
| SCHEMBL25569855 | 0.73 | AKR1B1 (0.36) | AKR1B1ALDH1A1GAAMAPT | |
| SCHEMBL1863391 | 0.73 | ALDH1A1 (0.47) | ALDH1A1GAAGFERMAPTPDK2 | |
| SCHEMBL24450547 | 0.73 | ESR1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL31173354 | 0.72 | PLAU (0.43) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | MTNR1A 755/4885MTNR1B 700/4885NR1H2 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.